State of Alaska Department of Revenue cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 25.6% during the 4th quarter, according to the company in its most ...

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...

Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CVS Health (CVS – Research Report) and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...